Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy

Current Pharmaceutical Biotechnology

Volumn 12, Issue 3, 2011, Pages 337-346

  Yilmaz, Taygan ^a   Cordero Coma, Miguel ^b   Lavaque, Alejandro J ^c   Gallagher, Michéal J ^d   Padula, William V ^e  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL DE LEÓN   (Spain)

^c San Miguel de Tucumán   (Argentina)

^d Hermitage Medical Clinic   (Ireland)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Diabetic macular oedema; Diabetic retinopathy; Implants; Sustained release; Triamcinolone acetonide; Vascular en dothelial growth factor

Indexed keywords

BETAMETHASONE; CORTISONE; DEOXYCORTICOSTERONE; DEXAMETHASONE; FLUDROCORTISONE; FLUOCINOLONE ACETONIDE; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISONE; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD RETINA BARRIER; CATARACT; CENTRAL RETINA ARTERY OCCLUSION; CILIARY DISK; CYTOMEGALOVIRUS RETINITIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENDOPHTHALMITIS; HALF LIFE TIME; HUMAN; IMPLANT; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; KERATITIS; RETINA MACULA HOLE; SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITRECTOMY;

ANTI-INFLAMMATORY AGENTS; BLOOD-RETINAL BARRIER; DELAYED-ACTION PREPARATIONS; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEMS; EYE; HUMANS; INJECTIONS, INTRAOCULAR; INTRAVITREAL INJECTIONS; MACULAR EDEMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 79551664779     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794480598     Document Type: Article

References (83)

1. AAO. Preferred Practice Patterns: Diabetic Retinopathy, Ameri can Academy of Ophthalmology: San Francisco, 1993.
2. Abraldes, M. J.; Fernandez, M.; Gomez-Ulla, F. Intravitreal triamcinolone in diabetic retinopathy. Curr. Diabetes Rev., 2009, 5(1), 18-25.
3. Cardillo, J. A.; Melo, L. A. Jr.; Costa, R. A.; Skaf, M.; Belfort, R., Jr.; Souza-Filho, A. A.; Farah, M. E.; Kuppermann, B. D. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology, 2005, 112(9), 1557-1563.
4. Gillies, M. C.; Simpson, J. M.; Gaston, C.; Hunt, G.; Ali, H.; Zhu, M.; Sutter, F. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology, 2009, 116(11), 2182-2187.
5. Kumar, V.; Ghosh, B.; Goel, N. Combined laser and intravitreal triamcinolone for proliferative diabetic retinopathy and macular edema. Am. J. Ophthalmol., 2009, 148(1), 171, 171-172.
6. Yam, J. C.; Kwok, A. K. Update on the treatment of diabetic retinopathy. Hong Kong Med. J., 2007, 13(1), 46-60.
7. Kuppermann, B. D.; Blumenkranz, M. S.; Haller, J. A.; Williams, G. A.; Weinberg, D. V.; Chou, C.; Whitcup, S. M. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthal-mol., 2007, 125(3), 309-317.
8. Lee, S. S.; Robinson, M. R. Novel drug delivery systems for retinal diseases. A review. Ophthalmic. Res., 2009, 41(3), 124-135.
9. Mohammad, D. A.; Sweet, B. V.; Elner, S. G. Retisert: is the new advance in treatment of uveitis a good one? Ann. Pharmacother., 2007, 41(3), 449-454.
10. Mruthyunjaya, P. Medidur insert technology. Retinal Phys., 2007, 25-28.
11. Hsu, J. Drug delivery methods for posterior segment disease. Curr. Opin. Ophthalmol., 2007, 18(3), 235-239.
12. DRCRN. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 2008, 115(9), 1447-1449.
13. Silva, P. S.; Sun, J. K.; Aiello, L. P. Role of steroids in the management of diabetic macular edema and proliferative diabetic reti-nopathy. Semin. Ophthalmol., 2009, 24(2), 93-99.
14. Yilmaz, T.; Weaver, C. D.; Gallagher, M. J.; Cordero-Coma, M.; Cervantes-Castaneda, R. A.; Klisovic, D.; Lavaque, A. J.; Larson, R. J. Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology, 2009, 116(5), 902-911.
15. Arimura, N.; Otsuka, H.; Yamakiri, K.; Sonoda, Y.; Nakao, S.; Noda, Y.; Hashiguchi, T.; Maruyama, I.; Sakamoto, T., Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology, 2009, 116(5), 921-926.
16. Ip, M. S.; Gottlieb, J. L.; Kahana, A.; Scott, I. U.; Altaweel, M. M.; Blodi, B. A.; Gangnon, R. E.; Puliafito, C. A. Intravitreal triamci-nolone for the treatment of macular edema associated with central retinal vein occlusion. Arch. Ophthalmol., 2004, 122(8), 1131-1136.
17. Jermak, C. M.; Dellacroce, J. T.; Heffez, J.; Peyman, G. A. Triam-cinolone acetonide in ocular therapeutics. Surv. Ophthalmol., 2007, 52(5), 503-522.
18. Unoki, N.; Nishijima, K.; Kita, M.; Suzuma, K.; Watanabe, D.; Oh, H.; Kimura, T.; Sakamoto, A.; Yoshimura, N. Randomised controlled trial of posterior sub-Tenon triamcinolone as adjunct to pan-retinal photocoagulation for treatment of diabetic retinopathy. Br. J. Ophthalmol., 2009, 93(6), 765-770.
19. Zimmerman, T. J.; Kooner, K.; Sharir, M.; Fechtner, R. D. Textbook of Ocular Pharmacology; Lippincott-Raven: Philadelphia, 1997.
20. Argenti, D.; Jensen, B. K.; Hensel, R.; Bordeaux, K.; Schleimer, R.; Bickel, C.; Heald, D. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration. J. Clin. Pharmacol., 2000, 40(7), 770-780.
21. Aiello, L. P.; Avery, R. L.; Arrigg, P. G.; Keyt, B. A.; Jampel, H. D.; Shah, S. T.; Pasquale, L. R.; Thieme, H.; Iwamoto, M. A.; Park, J. E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med., 1994, 331(22), 1480-1487.
22. Penfold, P. L.; Wen, L.; Madigan, M. C.; Gillies, M. C.; King, N. J.; Provis, J. M. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1(ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin. Exp. Immunol., 2000, 121(3), 458-465.
23. Jonas, J. B. Intraocular availability of triamcinolone acetonide after intravitreal injection. Am. J. Ophthalmol., 2004, 137(3), 560-562.
24. Vedantham, V.; Kolluru, C.; Ramasamy, K. Persistent depot of triamcinolone acetonide after a single intravitreal injection. Indian J. Ophthalmol., 2005, 53(1), 65-66.
25. Ahmadieh, H.; Ramezani, A.; Shoeibi, N.; Bijanzadeh, B.; Tabata-baei, A.; Azarmina, M.; Soheilian, M.; Keshavarzi, G.; Mohebbi, M. R. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes. Arch. Clin. Exp. Ophthalmol., 2008, 246(4), 483-489.
26. Audren, F.; Erginay, A.; Haouchine, B.; Benosman, R.; Conrath, J.; Bergmann, J. F.; Gaudric, A.; Massin, P. Intravitreal triamcinolone acetonide for diffuse diabetic macular oedema: 6-month results of a prospective controlled trial. Acta Ophthalmol. Scand., 2006, 84(5), 624-630.
27. Bonini-Filho, M. A.; Jorge, R.; Barbosa, J. C.; Calucci, D.; Cardillo, J. A.; Costa, R. A. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest. Ophthalmol. Vis. Sci., 2005, 46(10), 3845-3849.
28. Gillies, M. C.; Sutter, F. K.; Simpson, J. M.; Larsson, J.; Ali, H.; Zhu, M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology, 2006, 113, (9), 1533-1538.
29. Ockrim, Z. K.; Sivaprasad, S.; Falk, S.; Roghani, S.; Bunce, C.; Gregor, Z.; Hykin, P. Intravitreal triamcinolone versus laser photo-coagulation for persistent diabetic macular oedema. Br. J. Oph-thalmol., 2008, 92(6), 795-799.
30. Soheilian, M.; Ramezani, A.; Bijanzadeh, B.; Yaseri, M.; Ah-madieh, H.; Dehghan, M. H.; Azarmina, M.; Moradian, S.; Tabata-baei, H.; Peyman, G. A. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photo-coagulation as primary treatment of diabetic macular edema. Retina, 2007, 27(9), 1187-1195.
31. Soheilian, M.; Ramezani, A.; Obudi, A.; Bijanzadeh, B.; Sale-hipour, M.; Yaseri, M.; Ahmadieh, H.; Dehghan, M. H.; Azarmina, M.; Moradian, S.; Peyman, G. A. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology, 2009, 116(6), 1142-1150.
32. Dehghan, M. H.; Ahmadieh, H.; Ramezani, A.; Entezari, M.; Ani-sian, A. A randomized, placebo-controlled clinical trial of in-travitreal triamcinolone for refractory diabetic macular edema. Int. Ophthalmol., 2008, 28(1), 7-17.
33. Faghihi, H.; Roohipoor, R.; Mohammadi, S. F.; Hojat-Jalali, K.; Mirshahi, A.; Lashay, A.; Piri, N.; Faghihi, S. Intravitreal bevaci-zumab versus combined bevacizumab-triamcinolone versus macu-lar laser photocoagulation in diabetic macular edema. Eur. J. Oph-thalmol., 2008, 18(6), 941-948.
34. Jonas, J. B.; Kamppeter, B. A.; Harder, B.; Vossmerbaeumer, U.; Sauder, G.; Spandau, U. H. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J. Ocul. Pharmacol. Ther., 2006, 22(3), 200-207.
35. Hauser, D.; Bukelman, A.; Pokroy, R.; Katz, H.; Len, A.; Thein, R.; Parness-Yossifon, R.; Pollack, A. Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg. Retina, 2008, 28(6), 825-830.
36. Paccola, L.; Costa, R. A.; Folgosa, M. S.; Barbosa, J. C.; Scott, I. U.; Jorge, R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br. J. Ophthalmol., 2008, 92(1), 76-80.
37. Aydin, E.; Demir, H. D.; Yardim, H.; Erkorkmaz, U. Efficacy of intravitreal triamcinolone after or concomitant with laser photoco-agulation in nonproliferative diabetic retinopathy with macular edema. Eur. J. Ophthalmol., 2009, 19(4), 630-637.
38. Lam, D. S.; Chan, C. K.; Mohamed, S.; Lai, T. Y.; Lee, V. Y.; Liu, D. T.; Li, K. K.; Li, P. S.; Shanmugam, M. P. Intravitreal triamci-nolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes. Ophthalmology, 2007, 114(12), 2162-2167.
39. Chung, E. J.; Freeman, W. R.; Azen, S. P.; Lee, H.; Koh, H. J. Comparison of combination posterior sub-tenon triamcinolone and modified grid laser treatment with intravitreal triamcinolone treatment in patients with diffuse diabetic macular edema. Yonsei Med. J., 2008, 49(6), 955-964.
40. Lee, H. Y.; Lee, S. Y.; Park, J. S. Comparison of photocoagulation with combined intravitreal triamcinolone for diabetic macular edema. Korean J. Ophthalmol., 2009, 23(3), 153-158.
41. Maia, O. O., Jr.; Takahashi, B. S.; Costa, R. A.; Scott, I. U.; Taka-hashi, W. Y. Combined laser and intravitreal triamcinolone for pro-liferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am. J. Ophthalmol., 2009, 147(2), 291-297 e2.
42. Schwartz, S. G.; Flynn, H. W, Jr. Pharmacotherapies for diabetic retinopathy: present and future. Exp. Diabetes Res., 2007, 2007, 52487.
43. Zacks, D. N.; Johnson, M. W. Combined intravitreal injection of triamcinolone acetonide and panretinal photocoagulation for concomitant diabetic macular edema and proliferative diabetic reti-nopathy. Retina, 2005, 25(2), 135-140.
44. Zein, W. M.; Noureddin, B. N.; Jurdi, F. A.; Schakal, A.; Bashshur, Z. F. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina, 2006, 26(2), 137-142.
45. Larsson, J.; Kifley, A.; Zhu, M.; Wang, J. J.; Mitchell, P.; Sutter, F. K.; Gillies, M. C. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta. Ophthalmol., 2009, 87(3), 275-280.
46. Karacorlu, M.; Ozdemir, H.; Karacorlu, S.; Alacali, N. Regression of optic nerve head neovascularization in proliferative diabetic reti-nopathy after intravitreal triamcinolone. Regression of diabetic optic disc neovascularization after intravitreal triamcinolone. Int. Ophthalmol., 2004, 25(2), 113-116.
47. Jonas, J. B.; Kreissig, I.; Degenring, R. F. Neovascular glaucoma treated by intravitreal triamcinolone acetonide. Acta Ophthalmol. Scand., 2003, 81(5), 540-541.
48. Peyman, G. A.; Cheema, R.; Conway, M. D.; Fang, T. Triamci-nolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina, 2000, 20(5), 554-555.
49. Matsumoto, H.; Yamanaka, I.; Hisatomi, T.; Enaida, H.; Ueno, A.; Hata, Y.; Sakamoto, T.; Ogino, N.; Ishibashi, T. Triamcinolone acetonide-assisted pars plana vitrectomy improves residual posterior vitreous hyaloid removal: ultrastructural analysis of the inner limiting membrane. Retina, 2007, 27(2), 174-179.
50. Sakamoto, T.; Ishibashi, T. Visualizing vitreous in vitrectomy by triamcinolone. Graefes Arch. Clin. Exp. Ophthalmol., 2009, 247(9), 1153-1163.
51. Yamakiri, K.; Sakamoto, T.; Noda, Y.; Nakahara, M.; Ogino, N.; Kubota, T.; Yokoyama, M.; Furukawa, M.; Ishibashi, T. One-year results of a multicenter controlled clinical trial of triamcinolone in pars plana vitrectomy. Graefes Arch. Clin. Exp. Ophthalmol., 2008, 246(7), 959-966.
52. Yamakoshi, T.; Kachi, S.; Sugita, J.; Asami, T.; Ishikawa, K.; Ito, Y.; Terasaki, H. Triamcinolone-assisted removal of internal limiting membrane enhances the effect of vitrectomy for diabetic macu-lar edema. Ophthalmic. Res., 2009, 41(4), 203-209.
53. Lee, G. H.; Ahn, J. K.; Park, Y. G. Intravitreal triamcinolone reduces the morphologic changes of ciliary body after pars plana vitrectomy for retinal vascular diseases. Am. J. Ophthalmol., 2008, 145(6), 1037-1044.
54. Imasawa, M.; Ohshiro, T.; Gotoh, T.; Imai, M.; Iijima, H. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Oph-thalmol. Scand., 2005, 83(1), 132-133.
55. Cardillo, J. A.; Souza-Filho, A. A.; Oliveira, A. G. Intravitreal Bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema. Arch. Soc. Esp. Oftalmol., 2006, 81(12), 675-677+679-681.
56. Kiernan, D. F.; Mieler, W. F. The use of intraocular corticosteroids. Expert. Opin. Pharmacother., 2009, 10(15), 2511-2525.
57. Jaffe, G. J.; Martin, D.; Callanan, D.; Pearson, P. A.; Levy, B.; Comstock, T. Fluocinolone acetonide implant (Retisert) for nonin-fectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology, 2006, 113(6), 1020-1027.
58. Spencer, R. W.; Andelman, S. Y. Steroid cataracts. Posterior sub-capsular cataract formation in rheumatoid arthritis patients on long term steroid therapy. Arch. Ophthalmol., 1965, 74, 38-41.
59. Yoshimura, M.; Hirano, Y.; Nozaki, M.; Yoshida, M.; Ogura, Y. [Incidence of posterior subcapsular cataract progression after triamcinolone acetonide administration]. Nippon Ganka Gakkai Zasshi, 2008, 112(9), 786-789.
60. Jonas, J. B.; Kreissig, I.; Degenring, R. F. Cataract surgery after intravitreal injection of triamcinolone acetonide. Eye, (Lond) 2004, 18(4), 361-364.
61. Gillies, M. C.; Kuzniarz, M.; Craig, J.; Ball, M.; Luo, W.; Simpson, J. M. Intravitreal triamcinolone-induced elevated intraocular pressure is associated with the development of posterior subcapsular cataract. Ophthalmology, 2005, 112(1), 139-143.
62. Kuo, C. H.; McCluskey, P.; Gillies, M. Pharmacotherapeutic efficacy of preservative-free intravitreal triamcinolone acetonide. Exp. Opin. Pharmacother., 2010, 11(1), 155-166.
63. Nelson, M. L.; Tennant, M. T.; Sivalingam, A.; Regillo, C. D.; Belmont, J. B.; Martidis, A. Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina, 2003, 23(5), 686-691.
64. Agrawal, S.; Agrawal, J.; Agrawal, T. P. Conjunctival ulceration following triamcinolone injection. Am. J. Ophthalmol., 2003, 136(3), 539-540.
65. Jaissle, G. B.; Szurman, P.; Bartz-Schmidt, K.U. [Ocular side effects and complications of intravitreal triamcinolone acetonide injection]. Ophthalmologe, 2004, 101(2), 121-128.
66. Hashizume, K.; Nabeshima, T.; Fujiwara, T.; Machida, S.; Kuro-saka, D. A case of herpetic epithelial keratitis after triamcinolone acetonide subtenon injection. Cornea, 2009, 28(4), 463-464.
67. Angulo Bocco, M. C.; Glacet-Bernard, A.; Zourdani, A.; Coscas, G.; Soubrane, G. [Intravitreous injection: retrospective study on 2028 injections and their side effects]. J. Fr. Ophtalmol., 2008, 31(7), 693-698.
68. Valamanesh, F.; Berdugo, M.; Sennlaub, F.; Savoldelli, M.; Goumeaux, C.; Houssier, M.; Jeanny, J. C.; Torriglia, A.; Behar-Cohen, F. Effects of triamcinolone acetonide on vessels of the posterior segment of the eye. Mol. Vis., 2009, 15, 2634-2648.
69. Ferrucci, S. Diabetic macular edema: new solutions to an old problem? Rev. Optometry., 2009, 20-22.
70. Petrou, I. Intravitreal insert aims high in the treatment of DME. Ophthalmol. Times, 2009, 1-2.
71. Dafer, R. M.; Schneck, M.; Friberg, T. R.; Jay, W. M. Intravitreal ranibizumab and bevacizumab: a review of risk. Semin. Ophthal-mol., 2007, 22(3), 201-204.
72. Wu, L.; Martinez-Castellanos, M. A.; Quiroz-Mercado, H.; Are-valo, J. F.; Berrocal, M. H.; Farah, M. E.; Maia, M.; Roca, J. A.; Rodriguez, F. J. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch. Clin. Exp. Oph-thalmol., 2008, 246(1), 81-87.
73. Funatsu, H.; Yamashita, H.; Sakata, K.; Noma, H.; Mimura, T.; Suzuki, M.; Eguchi, S.; Hori, S. Vitreous levels of vascular endo-thelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology, 2005, 112(5), 806-816.
74. Arevalo, J. F.; Sanchez, J. G.; Fromow-Guerra, J.; Wu, L.; Berro-cal, M. H.; Farah, M. E.; Cardillo, J.; Rodriguez, F. J. Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse diabetic macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch. Clin. Exp. Ophthalmol., 2009, 247(6), 735-743.
75. Do, D. V.; Nguyen, Q. D.; Shah, S. M.; Browning, D. J.; Haller, J. A.; Chu, K.; Yang, K.; Cedarbaum, J. M.; Vitti, R. L.; Ingerman, A.; Campochiaro, P. A. An exploratory study of the safety, toler-ability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macu-lar oedema. Br. J. Ophthalmol., 2009, 93(2), 144-149.
76. Nguyen, Q. D.; Shah, S. M.; Heier, J. S.; Do, D. V.; Lim, J.; Boyer, D.; Abraham, P.; Campochiaro, P. A. Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology, 2009, 116(11), 2175-2181 e1.
77. Querques, G.; Bux, A. V.; Martinelli, D.; Iaculli, C.; Noci, N. D. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol., 2009, 87(6), 623-630.
78. Arevalo, J. F.; Wu, L.; Sanchez, J. G.; Maia, M.; Saravia, M. J.; Fernandez, C. F.; Evans, T. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye, (Lond) 2009, 23(1), 117-1123.
79. Jiang, Y.; Liang, X.; Li, X.; Tao, Y.; Wang, K. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy. Acta. Ophthalmol., 2009, 87(7), 736-740.
80. Mason, J. O., 3rd; Yunker, J. J.; Vail, R.; McGwin, G., Jr. In-travitreal bevacizumab (Avastin) prevention of panretinal photoco-agulation-induced complications in patients with severe prolifera-tive diabetic retinopathy. Retina, 2008, 28(9), 1319-1324.
81. Tonello, M.; Costa, R. A.; Almeida, F. P.; Barbosa, J. C.; Scott, I. U.; Jorge, R. Panretinal photocoagulation versus PRP plus in-travitreal bevacizumab for high-risk proliferative diabetic retinopa-thy (IBeHi study). Acta Ophthalmol., 2008, 86(4), 385-389.
82. Helbig, H. Surgery for diabetic retinopathy. Ophthalmologica, 2007, 221(2), 103-111.
83. Kuppermann, B. D.; Thomas, E. L.; de Smet, M. D.; Grillone, L. R. Pooled efficacy results from two multinational randomized controlled clinical trials of a single intravitreous injection of highly purified ovine hyaluronidase (Vitrase) for the management of vitreous hemorrhage. Am. J. Ophthalmol., 2005, 140(4), 573-584.